Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely

Pediatric Infectious Disease Journal

Volumn 26, Issue 9, 2007, Pages 824-829

  Omeñaca, Félix ^a   Garcia Sicilia, José ^a   Boceta, Reyes ^b   Sistiaga Hernando, Alessandra ^b   García Corbeira, Pilar ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

Children; Combination vaccine; DTaP HBV IPV Hib; Immunization; Preterm

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; GESTATIONAL AGE; HUMAN; IMMUNOGENICITY; NEWBORN; NORMAL HUMAN; PATIENT ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; VACCINATION;

CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; POLIOVIRUS VACCINES; PREGNANCY; PREMATURE BIRTH; SEROLOGIC TESTS; VACCINES, CONJUGATE;

EID: 34548252529     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318124a9c8     Document Type: Article

References (27)

1. Roberton DM, Marshall H, Dinan L, Boros C, Gold M. Developmental immunology and vaccines: immune responses to vaccines in premature infants. Expert Rev Vaccines. 2004;3:343-347.
2. D'Angio CT, Hall CB. Timing of vaccinations in premature infants. BioDrugs. 2000;13:335-346.
3. Langkamp DL, Hoshaw-Woodard S, Boye ME, Lemeshow S. Delays in receipt of immunizations in low-birth-weight children: a nationally representative sample. Arch Pediatr Adolesc Med. 2001;155:167-172.
4. Joint Commission on Immunization and Vaccination. Immunization Against Infectious Disease. London: HM Stationery Office; 1988.
5. Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 2003;112:193-198.
6. Bogaerts H. The future of childhood immunizations: examining the European experience. Am J Manag Care. 2003;9(1 suppl):S30-S36.
7. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 suppl):S6-S12.
8. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002;21:854-859.
9. Arístegui J, Dal-Ré R, Díez-Delgado J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21 3593-3600.
10. Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr. 2002;161:581-587.
11. Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate of mixed injections. J Pediatr. 2000;137:304-312.
12. Tejedor J-C, Omeñaca F, García-Sicilia J, et al. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine co-administered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J. 2004;23:1109-1115.
13. Tichmann I, Preidel H, Grunert D, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine. 2005;23:3272-3279.
14. Tichmann-Schumann I, Soemantri P, Behre U, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with a 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2005;24:70-77.
15. Zepp F, Knuf M, Heininger U, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine. 2004;22:2226-2233.
16. Gabutti G, Zepp F, Schuerman L, et al. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine coadministered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis. 2004;36:585-592.
17. Omeñaca F, Garcia-Sicilia J, García-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanusacellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005;116:1292-1298.
18. Omeñaca F, Garcia-Sicilia J, García-Corbeira P, Boceta R, Torres V. Anti-PRP response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics. 2007;119:e179-e185.
19. Kirmani KI, Lofthus G, Pichichero ME, Voloshen T, D'Angio CT. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics. 2002;109:498-504.
20. Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003;88:206-210.
21. Khalak R, Pichichero ME, D'Angio CT. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics. 1998;101(4, pt 1):597-603.
22. Esposito S, Faldella G, Giammanco A, et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine. 2002;20:2928-2932.
23. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis. 2000;31:973-980.
24. Slack MH, Schapira D, Thwaites RJ, et al. Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed. 2004;89:F269-F271.
25. Berrington JE, Cant AJ, Matthews JN, O'Keeffe M, Spickett GP, Fenton AC. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics. 2006;117:e717-e724.
26. Fitzsimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158-4166.
27. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14:196-198.